Retooling Your Immune System In Vivo to Fight Cancer - Multi-Functional Cell Therapies Summit - May 2021

Oct 28, 2026

A confidential presentation outlining Umoja’s in vivo immunotherapy platform aimed at improving access to immunotherapy by retooling a patient’s immune system. The talk describes integrated solutions for CAR-T challenges in blood and solid tumors, including fixed CAR specificity and universal TagCAR approaches. It details VivoVec for in vivo CAR T generation via lymph node delivery and subsequent tumor trafficking, and RACR for in vivo CAR T expansion controlled by a Rapamycin Activated Cytokine Receptor system. It also presents TumorTag combinatorial targeting using SMOL adapters and swappable tumor/stroma labels.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Our Mission

Umoja’s Integrated Immunotherapy Platform

VivoVec: In vivo CAR T Cell Generation

RACR: In vivo CAR T Cell Expansion

TumorTag: Combinatorial Tumor Targeting

Platform Goal

Your Body. Your Hope . Your Cure . Retooling Your Immune System In Vivo to Fight Cancer Mulit-Functional Cell Therapies Summit, May 2021 Our mission is to advance and improve access to immunotherapy by retooling the patient’s immune system in vivo, freeing them from the burden of cancer in their daily lives CONFIDENTIAL 2 Umoja’s integrated immunotherapy platform provides solutions to the challenges in both blood and solid tumor CAR-T therapies Fixed CAR specificity Universal TagCAR 3 VivoVec : In vivo CAR T cell generation Foundational concept: lymph nodes are nature’s optimized T cell “manufactory” Umoja leverages a deep understanding of the human immune system’s physiology for its proprietary approach to in vivo T cell engineering VivoVec particles are delivered to lymph nodes VivoVec particles bind, activate, and transduce Tcells Transduced Tcells exit lymph nodes and traffic to tumor CONFIDENTIAL 4 RACR: In vivo CAR T cell expansion RACR: Rapamycin Activated Cytokine Receptor provides control over expansion 3-component RACR system • Rapamycin activates the RACR system which replicates common g chain cytokine activating STAT5 signaling for robust proliferation and survival • Naked intracellular FRB domain provides rapamycin resistance to transduced cells while non transduced T and B cells are repressed through mTOR inhibition CONFIDENTIAL 5 TumorTag : Comb inatorial Tumor Targeting TumorTag platform: SMOL adapters for targeting of tumor and stroma TAG Tumor ligand universal fluorescein (FL)”Tag” antigen Swappable ligands Antigen-independent universal tumor label TumorTag SMOL adapter suite UB-TT170 (FL-folate) | | TagCAR T-cells
target tumor or stroma via“Tag” adapter bound to surface antigen | | | --- | --- | --- | CONFIDENTIAL 6 Umoja’s immunotherapy platform is designed to effectively and safely retool the patient’s immune system against cancer CONFIDENTIAL 7 Thank you UMOJA-BIOPHARMA. COM

FAQs

What is Umoja’s primary mission in this presentation?

To advance and improve access to immunotherapy by retooling the patient’s immune system in vivo, reducing the burden of cancer in daily life.

How does VivoVec generate CAR T cells in vivo?

VivoVec particles are delivered to lymph nodes, then bind, activate, and transduce T cells. The transduced T cells exit lymph nodes and traffic to the tumor.

What role does RACR play in CAR T expansion?

RACR provides control over in vivo CAR T expansion using a rapamycin-activated cytokine receptor system, enabling robust proliferation and survival while regulating undesired cell activity.

Oct 28, 2026

Upload by Blue Pony